Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Zhejiang Univ Sci B ; 11(3): 200-8, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20205306

RESUMEN

OBJECTIVE: To investigate the effects of mycotoxin moniliformin (MON) on the metabolism of aggrecan and type II collagen in human chondrocytes in vitro and the relationship between MON and Kashin-Beck disease (KBD). METHODS: Human chondrocytes were isolated and cultured on bone matrix gelatin to form an artificial cartilage model in vitro with or without MON toxin. Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The expression of aggrecan and type II collagen in the cartilage was determined using immunocytochemical staining. RESULTS: MON toxin inhibited chondrocyte viability in dose-dependent and time-dependent manners. MON reduced aggrecan and type II collagen syntheses in the tissue-engineered cartilage. MON also increased the expression of matrix metalloproteinase-1 (MMP-1), MMP-13, BC4 epitopes, and CD44 in cartilages. However, the expression of 3B3(-) epitopes in cartilages was inhibited by MON. Selenium partially alleviated the damage of aggrecan induced by MON toxin. CONCLUSION: MON toxin promoted the catabolism of aggrecan and type II collagen in human chondrocytes.


Asunto(s)
Enfermedades de los Cartílagos/inducido químicamente , Cartílago Articular/efectos de los fármacos , Condrocitos/efectos de los fármacos , Condrocitos/metabolismo , Ciclobutanos/toxicidad , Proteínas de la Matriz Extracelular/metabolismo , Selenio/administración & dosificación , Enfermedades de los Cartílagos/metabolismo , Cartílago Articular/metabolismo , Células Cultivadas , Ciclobutanos/administración & dosificación , Relación Dosis-Respuesta a Droga , Estudios de Factibilidad , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA